REMARKS

Applicants respectfully request reconsideration and reexamination of the present application in light of the amendments and the remarks below.

Claims 1, 2, 7, 13, 14, 25-28, 30, 32 35, 50, 51, 53-55, 62, and 63 are pending in this application. Claims 3-6, 8-12, 15-24, 29, 31, 33-34, 36-49, 52, 56-61, and 64-66 have been cancelled and claims 51, 53-54, and 62-63 have been withdrawn.

Claims 1 and 2 have been amended. Support for the amended claim may be found, for example, on pages 19 and 20 of the specification. These claim amendments are made to clarify the subject matter therein. Therefore, these amendments are submitted in order to place the claims in condition for allowance, and do not disclaim any subject matter to which the Applicants are entitled.

Sequence Compliance

The Examiner stated that the Applicants need to provide a statement indication that the electronic and paper copy of the sequence are identical and that no matter is included to comply with the sequence rules.

Applicants provided such statement on March 30, 2005. A copy has been provided.

Specification

The Examiner has objected to the specification because trademarks are disclosed throughout the instant specification and not all of them are capitalized or accompanied by the generic terminology. The specification has been amended as requested.

The Examiner has objected to the specification because the address for ATCC is incorrect. The specification has been amended as requested.

The Examiner has objected to the specification because it contains an embedded hyperlink and/or other form of browser-executable code. The specification has been amended as requested.

The Examiner has objected to the specification because the priority information is missing from the first page. The specification has been amended as requested.

Rejection Under 35 U.S.C. § 112, first paragraph

The Examiner rejected claims 1, 2, 7, 13, 14, 25-28, 30, 32, 35, 50, and 55 under 35 U.S.C. § 112, first paragraph, as failing to comply with written description requirement. The Examiner stated that the claims recite added material, which is not supported by the original disclosure. The claims recite "An

isolated or recombinant FVII or FVIIa" and the specification does not explicitly teach "an isolated FVII or FVIIa." The Examiner acknowledges that support was found for the term "recombinant." To expedite prosecution, the claims have been amended to recite "A recombinant Factor VII (FVII) or Factor VIIa (FVIIa) polypeptide variant."

The Examiner also stated that no support was found in the specification for the language "no more than 15 amino acid residues." The claims have been amended to clarify the subject matter therein.

It is thus submitted that the claims meet the requirements of 35 USC § 112, first paragraph, and reconsideration and withdrawal of the present rejection is respectfully requested.

Double Patenting

The Examiner has rejected claims 1, 2, 7, 13, 14, 25-28, 30, 32, 35, 50, and 55 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 3-20, 25, 31-43, 45-48 of co-pending U.S. Patent Application Serial No. 11/021,239; claims 1-5, 16-19, 26, 29-33, and 41-48 of co-pending U.S. Patent Application Serial No. 11/381,713; claims 1-5, 16-19, 26, 29-33, and 41-43, and 48 of co-pending U.S. Patent Application Serial No. 11/381,717; claims 1-5, 16-19, 26, 29-33, and 41-43, and 48 of co-pending U.S. Patent Application Serial No. 11/381,718; claims 1-5, 16-19, 26, 29-33, and 41-43, and 48 of co-pending U.S. Patent Application Serial No. 11/381,705; claims 1, 20, 25, 31-41, and 57-64 of co-pending U.S. Patent Application Serial No. 11/379,664; claims 1, 41, 48, 64-67, 82, 83, 91, 95, and 96 of co-pending U.S. Patent Application Serial No. 10/512,754; and claims 1, 3-17, 54, and 59 of co-pending U.S. Patent Application Serial No. 10/549,506.

It remains unknown what subject matter claimed and disclosed in the present application will be deemed allowable; hence any statement regarding this rejection made on Applicants' part would be premature. Therefore, Applicants respectfully traverse this rejection, and request that this rejection should be held in abeyance until subject matter is deemed allowable in this application.

CONCLUSION

For the foregoing reasons, Applicants submit that the claims are in condition for allowance and Applicants respectfully request reexamination of the present application, reconsideration and withdrawal of the present rejections and objections, and entry of the amendments. Should there be any further matter requiring consideration, Examiner Robinson is invited to contact the undersigned counsel.

If there are any further fees due in connection with the filing of the present reply, please charge the fees to undersigned's Deposit Account No. 03-4000. If a fee is required for an extension of time not accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,



Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972

Date: December 19, 2008

Bayer HealthCare LLC
800 Dwight Way
Berkeley, CA 94710
Telephone: (510) 705-7725
Facsimile: (510) 705-7904

Amendments to the Specification (Attorney Docket No. 0267U3210)

1) Please insert the following paragraph beginning at page 1, line 1:

This application is the national stage of International Patent Application No. PCT/DK2003/000632, filed on September 26, 2003, which claims the benefit of U.S. Provisional Patent Application Serial No. 60/479,642, filed on June 19, 2003 and U.S. Provisional Patent Application Serial No. 60/414,836, filed on September 30, 2002, the disclosures of each of which are incorporated by reference herein in their entirety for all purposes.

2) The paragraph beginning at page 22, line 1 should be replaced with the following replacement paragraph:

With markings:

In order to avoid to much disruption of the structure and function of the FVII or FVIIa polypeptide, the FVII or FVIIa polypeptide variant of the invention typically comprises an amino acid sequence having at least 95% identity with SEQ ID NO:1, such as at least 96% identity with SEQ ID NO:1, e.g. at least 97% identity with SEQ ID NO:1, at least 98% identity with SEQ ID NO:1, or at least 99% identity with SEQ ID NO:1. Amino acid sequence identity is conveniently determined from aligned sequences, using e.g. the ClustalW program, version 1.8, June 1999, using default parameters (Thompson et al., 1994, ClustalW: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Research, 22: 4673-4680) or from the PFAM families database version 4. 0 (~~http://~~pfam.wustl.edu/) *(Nucleic Acids Res*. 1999 Jan 1; 27(1):260-2) by use of GENEDOC version 2.5 (Nicholas, K.B., Nicholas H.B. Jr., and Deerfield, D.W. II. 1997 GeneDoc: Analysis and Visualization of Genetic Variation, EMBNEW.NEWS 4: 14; Nicholas, K.B. and Nicholas H.B. Jr. 1997 GeneDoc: Analysis and Visualization of Genetic Variation).

Without markings:

In order to avoid to much disruption of the structure and function of the FVII or FVIIa polypeptide, the FVII or FVIIa polypeptide variant of the invention typically comprises an amino acid sequence having at least 95% identity with SEQ ID NO:1, such as at least 96% identity with SEQ ID NO:1, e.g. at least 97% identity with SEQ ID NO:1, at least 98% identity with SEQ ID NO:1, or at least 99% identity with SEQ ID NO:1. Amino acid sequence identity is conveniently determined from aligned

sequences, using e.g. the ClustalW program, version 1.8, June 1999, using default parameters (Thompson et al., 1994, ClustalW: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Research, 22: 4673-4680) or from the PFAM families database version 4. 0 (pfam.wustl.edu/) *(Nucleic Acids Res.* 1999 Jan 1; 27(1):260-2) by use of GENEDOC version 2.5 (Nicholas, K.B., Nicholas H.B. Jr., and Deerfield, D.W. II. 1997 GeneDoc: Analysis and Visualization of Genetic Variation, EMBNEW.NEWS 4: 14; Nicholas, K.B. and Nicholas H.B. Jr. 1997 GeneDoc: Analysis and Visualization of Genetic Variation).

3) The paragraph beginning at page 48, line 1 should be replaced with the following replacement paragraph:

With markings:

Examples of suitable yeast host cells include strains of *Saccharomyces*, e.g. S. *cerevisiae*, *Schizosaccharomyces*, *Kluyveromyces*, *Pichia*, such as P. *pastoris* or P. methanolica, *Hansenula*, such as *H. Polymorpha* or *Yarrowia*. Yeast may be transformed using the procedures described by Becker and Guarente, *In* Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology,* Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *Journal of Bacteriology* 153: 163; Hinnen *et al.*, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1920: and as disclosed by Clontech Laboratories, Inc, Palo Alto, CA, USA (in the product protocol for the Yeastmaker™ Yeast Transformation System Kit). Examples of suitable insect host cells include a *Lepidoptora* cell line, such as *Spodoptera frugiperda* (Sf9 or Sf21) or *Trichoplusioa ni* cells (High Five) (US 5,077, 214). Transformation of insect cells and production of heterologous polypeptides therein may be performed as described by Invitrogen. Examples of suitable mammalian host cells include Chinese hamster ovary (CHO) cell lines, (e.g. CHO-K1; ATCC CCL-61), Green Monkey cell lines (COS) (e.g. COS l (ATCC CRL-1650), COS 7 (ATCC CRL-1651)); mouse s cells (e.g. NS/O), Baby Hamster Kidney (BHK) cell lines (e.g. ATCC CRL-1632 or ATCC CCL-10), and human cells (e.g. HEK 293 (ATCC CRL-1573)), as well as plant cells in tissue culture. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, ~~Rockville, Maryland~~ Manassas, VA. Also, the mammalian cell, such as a CHO cell, may be modified to express sialyltransferase, e.g. 1,6-sialyltransferase, e.g. as described in US 5,047,335, in order to provide improved glycosylation of the polypeptide variant.

Without markings:

Examples of suitable yeast host cells include strains of *Saccharomyces*, e.g. S. *cerevisiae*, *Schizosaccharomyces*, *Kluyveromyces*, *Pichia*, such as P. *pastoris* or P. methanolica, *Hansenula*, such as *H. Polymorpha* or *Yarrowia*. Yeast may be transformed using the procedures described by Becker and Guarente, *In* Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology*, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *Journal of Bacteriology* 153: 163; Hinnen *et al.*, 1978, *Proceedings of the National Academy of Sciences USA* 75: 1920: and as disclosed by Clontech Laboratories, Inc, Palo Alto, CA, USA (in the product protocol for the Yeastmaker™ Yeast Transformation System Kit). Examples of suitable insect host cells include a *Lepidoptora* cell line, such as *Spodoptera frugiperda* (Sf9 or Sf21) or *Trichoplusioa ni* cells (High Five) (US 5,077, 214). Transformation of insect cells and production of heterologous polypeptides therein may be performed as described by Invitrogen. Examples of suitable mammalian host cells include Chinese hamster ovary (CHO) cell lines, (e.g. CHO-K1; ATCC CCL-61), Green Monkey cell lines (COS) (e.g. COS l (ATCC CRL-1650), COS 7 (ATCC CRL-1651)); mouse s cells (e.g. NS/O), Baby Hamster Kidney (BHK) cell lines (e.g. ATCC CRL-1632 or ATCC CCL-10), and human cells (e.g. HEK 293 (ATCC CRL-1573)), as well as plant cells in tissue culture. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Manassas, VA. Also, the mammalian cell, such as a CHO cell, may be modified to express sialyltransferase, e.g. 1,6-sialyltransferase, e.g. as described in US 5,047,335, in order to provide improved glycosylation of the polypeptide variant.

4) The paragraph beginning at page 48, line 26 should be replaced with the following replacement paragraph:

With markings:

Methods for introducing exogeneous DNA into mammalian host cells include calcium phosphate-mediated transfection, electroporation, DEAE-dextran mediated transfection, liposome-mediated transfection, viral vectors and the transfection method described by Life Technologies Lt,. Paisley, UK using ~~Lipofectamine~~ Lipofectamine™ 2000. These methods are well known in the art and e.g. described by Ausbel et al. (eds.), 1996, Current Protocols in Molecular Biology, John Wiley & Sons, New York, USA. The cultivation of mammalian cells are conducted according to established methods, e.g. as disclosed in Animal Cell Biotechnology, Methods and Protocols, Edited by Nigel Jenkins, 1999, Human Press Inc, Totowa, New Jersey, USA and Harrison MA and Rae IF, General Techniques of Cell Culture, Cambridge University Press 1997.

Without markings:

Methods for introducing exogeneous DNA into mammalian host cells include calcium phosphate-mediated transfection, electroporation, DEAE-dextran mediated transfection, liposome-mediated transfection, viral vectors and the transfection method described by Life Technologies Lt,. Paisley, UK using Lipofectamine™ 2000. These methods are well known in the art and e.g. described by Ausbel et al. (eds.), 1996, Current Protocols in Molecular Biology, John Wiley & Sons, New York, USA. The cultivation of mammalian cells are conducted according to established methods, e.g. as disclosed in Animal Cell Biotechnology, Methods and Protocols, Edited by Nigel Jenkins, 1999, Human Press Inc, Totowa, New Jersey, USA and Harrison MA and Rae IF, General Techniques of Cell Culture, Cambridge University Press 1997.

5) The paragraph beginning at page 56, line 23 should be replaced with the following replacement paragraph:

With markings:

Non-ionic surfactants or detergents (also known as "wetting agents") may be present to help solubilizing the therapeutic agent as well as to protect the therapeutic polypeptide against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stress without causing denaturation of the polypeptide. Suitable non-ionic surfactants include polysorbates (20, 80, etc.), polyoxamers (184, 188 etc.), Pluronic® polyols, polyoxyethylene sorbitan monoethers (Tween®-20 (polyoxyethylenesorbitan monolaurate), Tween®-80 (polyoxyethylenesorbitan monooleate), etc.).

Without markings:

Non-ionic surfactants or detergents (also known as "wetting agents") may be present to help solubilizing the therapeutic agent as well as to protect the therapeutic polypeptide against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stress without causing denaturation of the polypeptide. Suitable non-ionic surfactants include polysorbates (20, 80, etc.), polyoxamers (184, 188 etc.), Pluronic® polyols, polyoxyethylene sorbitan monoethers (Tween®-20 (polyoxyethylenesorbitan monolaurate), Tween®-80 (polyoxyethylenesorbitan monooleate), etc.).

6) The paragraph beginning at page 60, line 31 should be replaced with the following replacement paragraph:

With markings:

The clotting activity of the FVIIa and variants thereof were measured in one-stage assays and the clotting times were recorded on a Thrombotrack® IV coagulometer (Medinor). Factor VII-depleted human plasma (American Diagnostica) was reconstituted and equilibrated at room temperature for 15-20 minutes. 50 microliters of plasma was then transferred to the coagulometer cups.

Without markings:

The clotting activity of the FVIIa and variants thereof were measured in one-stage assays and the clotting times were recorded on a Thrombotrack® IV coagulometer (Medinor). Factor VII-depleted human plasma (American Diagnostica) was reconstituted and equilibrated at room temperature for 15-20 minutes. 50 microliters of plasma was then transferred to the coagulometer cups.

7) The paragraph beginning at page 61, line 8 should be replaced with the following replacement paragraph:

With markings:

To measure the clotting activity in the absence of TF the same assay was used without addition of thromboplastin. Data was analysed using PRISM® software.

Without markings:

To measure the clotting activity in the absence of TF the same assay was used without addition of thromboplastin. Data was analysed using PRISM® software.

8) The paragraph beginning at page 61, line 12 should be replaced with the following replacement paragraph:

With markings:

The clotting activity of the FVIIa and variants thereof were measured in one-stage assays and the clotting times were recorded on a Thrombotrack® IV coagulometer (Medinor). 100 µl of FVIIa or variants thereof were diluted in a buffer containing 10 mM glycylglycine, 50 mM NaCl, 37.5 mM $CaCl_2$, pH 7.35 and transferred to a reaction cup. The clotting reaction was initiated by addition of 50 µl blood

containing 10% 0.13 M tri-sodium citrate as anticoagulant. Data was analyzed using Excel® or PRISM® software.

Without markings:

The clotting activity of the FVIIa and variants thereof were measured in one-stage assays and the clotting times were recorded on a Thrombotrack® IV coagulometer (Medinor). 100 µl of FVIIa or variants thereof were diluted in a buffer containing 10 mM glycylglycine, 50 mM NaCl, 37.5 mM $CaCl_2$, pH 7.35 and transferred to a reaction cup. The clotting reaction was initiated by addition of 50 µl blood containing 10% 0.13 M tri-sodium citrate as anticoagulant. Data was analyzed using Excel® or PRISM® software.

9) The paragraph beginning at page 61, line 30 should be replaced with the following replacement paragraph:

With markings:

FVII/FVIIa (or variant) concentrations are determined by ELISA. Wells of a microtiter plate are coated with an antibody directed against the protease domain using a solution of 2 µg/ml in PBS (100 µl per well). After overnight coating at R.T., the wells are washed 4 times with THT buffer (100 mM NaCl, 50 mM Tris-HCl pH 7.2 0.05% Tween®-20 (polyoxyethylenesorbitan monolaurate)). Subsequently, 200 µl of 1% Casein (diluted from 2.5% stock using 100 mM NaCl, 50 mM Tris-HCl pH 7.2) is added per well for blocking. After 1 hr incubation at R.T., the wells are emptied, and 100 µl of sample (optionally diluted in dilution buffer (THT + 0.1% Casein)) is added. After another incubation of 1 hr at room temperature, the wells are washed 4 times with THT buffer, and 100 µl of a biotin-labelled antibody directed against the EGF-like domain (1 µg/ml) is added. After another 1 hr incubation at R.T. , followed by 4 more washes with THT buffer, 100 µl of streptavidin-horse radish peroxidase (DAKO A/S, Glostrup, Denmark, 1/10000 diluted) is added. After another 1 hr incubation at R.T., followed by 4 more washes with THT buffer, 100 µl of TMB (3,3',5,5'-tetramethylbenzidine, Kem-en-Tech A/S, Denmark) is added. After 30 min incubation at R.T. in the dark, 100 µl of 1 M H2SO4 is added and OD_{450nm} is determined. A standard curve is prepared using rhFVIIa (NovoSeven®).

Without markings:

FVII/FVIIa (or variant) concentrations are determined by ELISA. Wells of a microtiter plate are coated with an antibody directed against the protease domain using a solution of 2 µg/ml in PBS (100 µl

per well). After overnight coating at R.T., the wells are washed 4 times with THT buffer (100 mM NaCl, 50 mM Tris-HCl pH 7.2 0.05% Tween®-20 (polyoxyethylenesorbitan monolaurate)). Subsequently, 200 µl of 1% Casein (diluted from 2.5% stock using 100 mM NaCl, 50 mM Tris-HCl pH 7.2) is added per well for blocking. After 1 hr incubation at R.T., the wells are emptied, and 100 µl of sample (optionally diluted in dilution buffer (THT + 0.1% Casein)) is added. After another incubation of 1 hr at room temperature, the wells are washed 4 times with THT buffer, and 100 µl of a biotin-labelled antibody directed against the EGF-like domain (1 µg/ml) is added. After another 1 hr incubation at R.T. , followed by 4 more washes with THT buffer, 100 µl of streptavidin-horse radish peroxidase (DAKO A/S, Glostrup, Denmark, 1/10000 diluted) is added. After another 1 hr incubation at R.T., followed by 4 more washes with THT buffer, 100 µl of TMB (3,3',5,5'-tetramethylbenzidine, Kem-en-Tech A/S, Denmark) is added. After 30 min incubation at R.T. in the dark, 100 µl of 1 M H2SO4 is added and OD_{450nm} is determined. A standard curve is prepared using rhFVIIa (NovoSeven®).

10) The paragraph beginning at page 68, line 12 should be replaced with the following replacement paragraph:

With markings:

The cell line CHO K1 (ATCC # CCL-61) is seeded at 50% confluence in T-25 flasks using MEMα, 10% FCS (Gibco/BRL, Cat # 10091), P/S and 5 µg/ml phylloquinone and allowed to grow until confluent. The confluent mono cell layer is transfected with 5 µg of the relevant plasmid described above using the ~~Lipofectamine~~ Lipofectamine™ 2000 transfection agent (Life ~~technologies~~ Technologies) according to the manufacturer's instructions. Twenty four hours post transfection a sample is drawn and quantified using *e.g.* an ELISA recognizing the EGF1 domain of hFVII. At this time point relevant selection (e.g. Hygromycin B) may be applied to the cells with the purpose of generating a pool of stable transfectants. When using CHO K1 cells and the Hygromycin B resistance gene as selectable marker on the plasmid, this is usually achieved within one week.

Without markings:

The cell line CHO K1 (ATCC # CCL-61) is seeded at 50% confluence in T-25 flasks using MEMα, 10% FCS (Gibco/BRL, Cat # 10091), P/S and 5 µg/ml phylloquinone and allowed to grow until confluent. The confluent mono cell layer is transfected with 5 µg of the relevant plasmid described above using the Lipofectamine™ 2000 transfection agent (Life Technologies) according to the manufacturer's instructions. Twenty four hours post transfection

a sample is drawn and quantified using *e.g.* an ELISA recognizing the EGF1 domain of hFVII. At this time point relevant selection (e.g. Hygromycin B) may be applied to the cells with the purpose of generating a pool of stable transfectants. When using CHO K1 cells and the Hygromycin B resistance gene as selectable marker on the plasmid, this is usually achieved within one week.

11) The paragraph beginning at page 69, line 17 should be replaced with the following replacement paragraph:

With markings:

The eluate from the first chromatographic step was loaded directly onto a second and final chromatographic column, which consisted of a POROS® HQ50 column pre-equilibrated with 10 mM Tris, 25 mM NaCl, 5 mM EDTA, pH 8.6. FVIIa was eluted from the POROS® HQ50 column using 10 mM Tris, 25 mM NaCl, 35 mM $CaCl_2$, pH 7.5 after washing the column with 10 mM Tris, 25 mM NaCl, pH 8.6. FVIIa eluted from the POROS® HQ50 column was stored at-80°C without further modification.

Without markings:

The eluate from the first chromatographic step was loaded directly onto a second and final chromatographic column, which consisted of a POROS® HQ50 column pre-equilibrated with 10 mM Tris, 25 mM NaCl, 5 mM EDTA, pH 8.6. FVIIa was eluted from the POROS® HQ50 column using 10 mM Tris, 25 mM NaCl, 35 mM $CaCl_2$, pH 7.5 after washing the column with 10 mM Tris, 25 mM NaCl, pH 8.6. FVIIa eluted from the POROS® HQ50 column was stored at-80°C without further modification.

12) The paragraph beginning at page 69, line 26 should be replaced with the following replacement paragraph:

With markings:

FVII and FVII variants are purified as follows: The procedure is performed at 4°C. The harvested culture media from large-scale production is ultrafiltered using a Millipore TFF system with 30 KDa cut-off Pellicon membranes. After concentration of the medium, citrate is added to 5 mM and the pH is adjusted to 8.6. If necessary, the conductivity is lowered to below 10 mS/cm. Subsequently, the sample is applied to a ~~Q sepharose~~ Q-Sepharose™ FF column, equilibrated with 50 mM NaCl, 10 mM Tris pH 8.6. After washing the column with 100 mM NaCl, 10 mM Tris pH 8.6, followed by 150 mM NaCl, 10 mM Tris pH 8.6, FVII is eluted using 10 mM Tris, 25 mM NaCl, 35 mM $CaCl_2$, pH 8.6.

Without markings:

FVII and FVII variants are purified as follows: The procedure is performed at 4°C. The harvested culture media from large-scale production is ultrafiltered using a Millipore TFF system with 30 KDa cut-off Pellicon membranes. After concentration of the medium, citrate is added to 5 mM and the pH is adjusted to 8.6. If necessary, the conductivity is lowered to below 10 mS/cm. Subsequently, the sample is applied to a Q-Sepharose™ FF column, equilibrated with 50 mM NaCl, 10 mM Tris pH 8.6. After washing the column with 100 mM NaCl, 10 mM Tris pH 8.6, followed by 150 mM NaCl, 10 mM Tris pH 8.6, FVII is eluted using 10 mM Tris, 25 mM NaCl, 35 mM $CaCl_2$, pH 8.6.

13) The paragraph beginning at page 70, line 1 should be replaced with the following replacement paragraph:

With markings:

For the second chromatographic step, an affinity column is prepared by coupling of a monoclonal Calcium-dependent antiGla-domain antibody to CNBr-activated Sepharose™ FF. About 5.5 mg antibody is coupled per ml resin. The column is equilibrated with 10 mM Tris, up to 100 mM NaCl, 35 mM $CaCl_2$, pH 7.5. NaCl is added to the sample to a concentration of 100 mM NaCl and the pH is adjusted to 7. 4-7.6. After O/N application of the sample, the column is washed with up to 100 mM NaCl, 35 mM $CaCl_2$, 10 mM Tris pH 7.5, and the FVII protein is eluted with 100 mM NaCl, 50 mM citrate, 75 mM Tris pH 7.5.

Without markings:

For the second chromatographic step, an affinity column is prepared by coupling of a monoclonal Calcium-dependent antiGla-domain antibody to CNBr-activated Sepharose™ FF. About 5.5 mg antibody is coupled per ml resin. The column is equilibrated with 10 mM Tris, up to 100 mM NaCl, 35 mM $CaCl_2$, pH 7.5. NaCl is added to the sample to a concentration of 100 mM NaCl and the pH is adjusted to 7. 4-7.6. After O/N application of the sample, the column is washed with up to 100 mM NaCl, 35 mM $CaCl_2$, 10 mM Tris pH 7.5, and the FVII protein is eluted with 100 mM NaCl, 50 mM citrate, 75 mM Tris pH 7.5.

14) The paragraph beginning at page 70, line 8 should be replaced with the following replacement paragraph:

With markings:

For the third chromatographic, the conductivity of the sample is lowered to below 10 mS/cm, if necessary, and the pH is adjusted to 8.6. The sample is then applied to a ~~Q sepharose~~ Q-Sepharose™ column (equilibrated with 50 mM NaCl, 10 mM Tris pH 8.6) at a density around 3-5 mg protein per ml gel to obtain efficient activation. After application, the column is washed with 50 mM NaCl, 10 mM Tris pH 8.6 for about 4 hours with a flow of 3-4 column volumes (cv) per hour. The FVII protein is eluted using a gradient of 0-100% of 500 mM NaCl, 10 mM Tris pH 8.6 over 40 cv. FVII containing fractions are pooled.

With markings:

For the third chromatographic, the conductivity of the sample is lowered to below 10 mS/cm, if necessary, and the pH is adjusted to 8.6. The sample is then applied to a Q-Sepharose™ column (equilibrated with 50 mM NaCl, 10 mM Tris pH 8.6) at a density around 3-5 mg protein per ml gel to obtain efficient activation. After application, the column is washed with 50 mM NaCl, 10 mM Tris pH 8.6 for about 4 hours with a flow of 3-4 column volumes (cv) per hour. The FVII protein is eluted using a gradient of 0-100% of 500 mM NaCl, 10 mM Tris pH 8.6 over 40 cv. FVII containing fractions are pooled.

15) The paragraph beginning at page 70, line 15 should be replaced with the following replacement paragraph:

With markings:

For the final chromatographic step, the conductivity is lowered to below 10 mS/cm. Subsequently, the sample is applied to a ~~Q sepharose~~ Q-Sepharose™ column (equilibrated with 140 mM NaCl, 10 mM glycylglycine pH 8.6) at a concentration of 3-5 mg protein per ml gel. The column is then washed with 140 mM NaCl, 10 mM glycylglycine pH 8.6 and FVII is eluted with 140 mM NaCl, 15 mM $CaCl_2$, 10 mM glycylglycine pH 8.6. The eluate is diluted to 10 mM $CaCl_2$ and the pH is adjusted 6.8-7.2. Finally, ~~Tween 80~~ Tween®-80 (polyoxyethylenesorbitan monooleate) is added to 0.01% and the pH is adjusted to 5.5 for storage at-80°C.

Without markings:

For the final chromatographic step, the conductivity is lowered to below 10 mS/cm. Subsequently, the sample is applied to a Q-Sepharose™ column (equilibrated with 140 mM NaCl, 10 mM glycylglycine pH 8.6) at a concentration of 3-5 mg protein per ml gel. The column is then washed with 140 mM NaCl, 10 mM glycylglycine pH 8.6 and FVII is eluted with 140 mM NaCl, 15 mM $CaCl_2$, 10 mM glycylglycine pH 8.6. The eluate is diluted to 10 mM $CaCl_2$ and the pH is adjusted 6.8-7.2. Finally, Tween®-80 (polyoxyethylenesorbitan monooleate) is added to 0.01% and the pH is adjusted to 5.5 for storage at-80°C.

Amended Claims (Attorney Docket No. 0267US310)

1. (Currently Amended) ~~An isolated or~~ A recombinant Factor VII (FVII) or Factor VIIa (FVIIa) polypeptide variant comprising an amino acid substitution ~~sequence which differs from the amino acid sequence of human Factor VII (hFVII) or human Factor VIIa (hFVIIa) shown in SEQ ID NO:1 with in no more than 15 amino acid residues~~, wherein the leucine (L) in position 65 of SEQ ID NO:1 is substituted with a glutamine (Q) in said variant sequence, and wherein amino acid positions of the variant sequence are numbered according to SEQ ID NO:1.

2. (Currently Amended) The variant according to claim 1, wherein said variant sequence further comprises at least one amino acid substitution selected from the group consisting of L39E, L39Q, L39H, I42R, S43H, S43Q, K62E, K62R, ~~L65S~~, F71D, F71Y, F71E, F71Q, F71N, E82Q, E82N, E82K, and F275H.

3-6. (Cancelled).

7. (Previously presented) The variant according to claim 2, wherein said at least one amino acid substitution is F71Y, K62E or S43Q.

8-12. (Cancelled).

13. (Previously presented) The variant according to claim 1, wherein said variant further comprises at least one amino acid substitution in the Gla domain.

14. (Previously presented) The variant according to claim 13, wherein said at least one amino acid substitution in the Gla domain is selected from the group consisting of P10, K32, D33 and A34.

15-24. (Cancelled).

25. (Previously presented) The variant according to claim 1, wherein an amino acid residue comprising an attachment group for a non-polypeptide moiety has been introduced in the variant sequence in a position located outside the Gla domain.

26. (Previously presented) The variant according to claim 25, wherein the non-polypeptide moiety is covalently attached to the attachment group.

27. (Original) The variant according to claim 26, wherein said non-polypeptide moiety is a sugar moiety.

28. (Previously presented) The variant according to claim 25, wherein said attachment group is a glycosylation site.

29. (Cancelled).

30. (Previously presented) The variant according to claim 28, wherein said glycosylation site is introduced by amino acid substitution.

31. (Cancelled).

32. (Previously presented) The variant according to claim 30, wherein said introduced glycosylation site is an N-glycosylation site.

33-34. (Cancelled).

35. (Previously presented) The variant according to claim 32, wherein said N-glycosylation site is introduced by a substitution selected from the group consisting of A51N, G58N, G48N+S60T, T106N, K109N, G124N, K143N+N145T, A175T, I205S, I205T, V253N, T267N, T267N+S269T, S314N+K316S, S314N+K316T, R315N+V317S, R315N+V317T, K316N+G318S, K316N+G318T, G318N, and D334N.

36-49. (Cancelled).

50. (Previously presented) The variant according to claim 1, wherein said variant is in its activated form.

51. (Withdrawn) A nucleotide sequence encoding the variant according to claim 1.

52. (Cancelled).

53. (Withdrawn) A host cell comprising the nucleotide sequence according to claim 51.

54. (Withdrawn) The host cell according to claim 53, wherein said host cell is a gammacarboxylating cell capable of *in vivo* glycosylation.

55. (Previously presented) A pharmaceutical composition comprising the variant of claim 1, and a pharmaceutically acceptable carrier or excipient.

56-61. (Cancelled).

62. (Withdrawn) A method for treating a mammal having a disease or a disorder wherein clot formation is desirable, comprising administering to a mammal in need thereof an effective amount of the pharmaceutical composition according to claim 55.

63. (Withdrawn) The method of claim 62, wherein said disease or disorder is selected from the group consisting of a hemorrhage, uncontrolled bleeding, cirrhosis, thrombocytopenia, and hemophilia.

64-66. (Cancelled).

"Express Mail" Label No. EV 332 431 699 US
Date of Deposit: March 30, 2005

I hereby certify that this is being deposited with the US Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above, addressed to: Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

By: Joanne R. Petithory
Joanne R. Petithory

Attorney Docket No: 0267us310

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Jesper Mortensen Haaning, *et al.*

US National Phase Application of
International Application Number:
PCT/DK2003/000632
International Filing Date: Sept. 26, 2003

US Application No.: *not yet assigned*

For: FVII OR FVIIA VARIANTS HAVING INCREASED CLOTTING ACTIVITY

Examiner: *not yet assigned*

Art Unit: *not yet assigned*

Statement Verifying Identity of Paper and CRF copies under 37 CFR §1.821(f)

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

I hereby state that the Sequence Listing information recorded on computer readable form (CRF) on the diskette submitted herewith is identical to the paper copy of the Sequence Listing submitted herewith.

Respectfully submitted,

Joanne R. Petithory

Joanne R. Petithory, Ph.D.
Reg. No. 42,995

Maxygen, Inc.
Intellectual Property Department
515 Galveston Drive
Redwood City, CA 94063
Phone: (650) 298-5452 (direct)
Fax: (650) 298-5446
Customer Number 30560